ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Meeting Abstract

cited authors

  • Miklos, David; Bharadwaj, Sushma; Holmes, Houston; Oluwole, Olalekan; Jallouk, Andrew; Neelapu, Sattva; Jain, Nitin; Nath, Rajneesh; Munoz, Javier; Bryan, Locke; De Vos, Sven; Eradat, Herbert; Patel, Rushang; Tees, Michael; Tsai, Stephanie; Cahill, Kirk; Sohl, Melhem; Shouse, Geoffrey; Stevens, Don; Fisher, Paul; Feng, Amy; Severyn, Christopher; Le Gall, John; Locke, Frederick; Pinilla, Javier

Publication Date

  • September 1, 2024

webpage

published in

category

start page

  • S604

end page

  • S604

volume

  • 24